USD/CNY: Policy support and stable fix – Commerzbank
Commerzbank’s Charlie Lay and Henry Hao note that the People's Bank of China (PBoC) kept benchmark lending rates at record lows for an 11th straight month, with the one-year LPR at 3.0% and five-year at 3.5%. Strong 5% year-on-year Q1 Gross Domestic Product (GDP) growth has reduced pressure for broad rate cuts, while USD/CNY and USD/CNH remain near their strongest levels since early 2023.
PBoC holds LPR as growth supports
"The People's Bank of China (PBoC) kept its benchmark lending rates unchanged at record lows for the 11th consecutive month in April. Matching market expectations, the central bank held the one-year loan prime rate (LPR) at 3.0% and the mortgage-linked five-year LPR at 3.5%."
"This decision to stand pat follows the stronger-than-expected first quarter GDP expansion of 5% yoy."
"With the economy expanding at the upper end of Beijing's 4.5% to 5% annual growth target, the PBoC has the flexibility to pause and assess the ongoing recovery trajectory."
"Moving forward, the central bank has committed to maintaining a supportive and moderately loose policy stance to shore up domestic activity while preserving currency stability."
"In FX, USD/CNY and USD/CNH were flat at around 6.82 yesterday, remaining near their strongest levels since early 2023."
(This article was created with the help of an Artificial Intelligence tool and reviewed by an editor.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market
Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.
Crypto prices
More
